What's Happening?
Researchers at City of Hope, in collaboration with Memorial Sloan Kettering Cancer Center and Seres Therapeutics, have developed a novel therapy, SER-155, to prevent dangerous bloodstream infections in blood cancer patients undergoing donor stem cell
transplants. This first-of-its-kind treatment utilizes 16 carefully selected beneficial bacteria to restore the microbiome and combat harmful pathogens. A multicenter phase 1 clinical trial demonstrated that SER-155 was well-tolerated, with no treatment-related side effects. Patients who received the therapy experienced fewer bloodstream infections and reduced levels of harmful bacteria associated with infection. This study, published in Nature Medicine, provides early evidence that live biotherapeutics can be safely administered to highly vulnerable patients, potentially preventing serious infections. Dr. Marcel van den Brink, City of Hope chief physician executive and senior author, highlighted that this marks the first time a consortium of beneficial bacteria has been designed for a specific clinical purpose and safely delivered to such patients, opening avenues for new classes of therapies.
Why It's Important?
This development is significant for cancer care, particularly for patients undergoing allogeneic stem cell transplantation, a life-saving but high-risk treatment for blood cancers. These patients are highly susceptible to infections due to compromised immune systems, with bloodstream infections being a leading cause of sepsis and mortality. Current preventative measures primarily involve antibiotics, which can disrupt the microbiome further. SER-155 offers a targeted approach to address the underlying microbiome disruption, potentially reducing reliance on broad-spectrum antibiotics and mitigating antibiotic resistance. The ability to precisely engineer a bacterial consortium for therapeutic outcomes represents a paradigm shift from general microbiome replenishment, offering a safer and more effective alternative to less controlled methods like fecal transplants for immunocompromised individuals. This precision medicine approach could significantly improve patient outcomes and quality of life during a critical phase of cancer treatment.
What's Next?
Before SER-155 can be widely available, larger clinical trials are necessary to further validate its efficacy and safety. The research team at City of Hope plans to conduct follow-up studies and clinical trials to develop additional microbiome-targeting therapies, particularly as a strategy to enhance immunotherapy. Beyond this specific therapy, the study's success in safely delivering a designed bacterial consortium to vulnerable patients paves the way for an entirely new class of live biotherapeutic drugs. This could lead to the development of similar precision microbiome engineering approaches for various other medical conditions where microbiome dysbiosis plays a role. Patients are advised to discuss responsible antibiotic use with their doctors, consume high-fiber diets to support beneficial bacteria, and avoid over-the-counter probiotics, which may contain strains detrimental to immunocompromised individuals.
Beyond the Headlines
This research delves into the profound impact of the microbiome on human health and disease, particularly in the context of cancer treatment. It highlights a shift from merely observing the microbiome to actively engineering it for specific therapeutic benefits, marking a significant advancement in personalized medicine. The ethical implications of manipulating the human microbiome are also brought to the forefront, emphasizing the need for rigorous scientific validation and safety protocols, especially when dealing with vulnerable patient populations. This targeted approach contrasts with broader interventions like fecal transplants, offering a more controlled and potentially safer alternative. The success of SER-155 could inspire further exploration into how microbial communities can be harnessed to modulate immune responses, combat pathogens, and improve overall patient resilience, potentially transforming how we approach infectious diseases and chronic conditions.
